Company Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
139.4 USD +0.24% Intraday chart for Neurocrine Biosciences, Inc. +0.60% +5.83%

Business Summary

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson's disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).

Number of employees: 1,400

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceuticals
100.0 %
1,489 100.0 % 1,887 100.0 % +26.76%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
1,489 100.0 % 1,887 100.0 % +26.76%

Managers

Managers TitleAgeSince
Founder 66 91-12-31
Director of Finance/CFO 44 17-10-31
Chief Tech/Sci/R&D Officer 60 21-11-29
Chief Tech/Sci/R&D Officer 60 18-01-07
Chief Operating Officer - 96-08-31
Chief Tech/Sci/R&D Officer 65 92-12-31
Director/Board Member 73 93-01-31
Investor Relations Contact - -
General Counsel - 20-12-31
Corporate Officer/Principal 44 19-09-29

Members of the board

Members of the board TitleAgeSince
Director/Board Member 75 99-03-31
Director/Board Member 72 15-09-30
Founder 66 91-12-31
Director/Board Member 71 23-07-10
Chairman 75 10-02-07
Director/Board Member 62 98-03-31
Director/Board Member 73 93-01-31
Director/Board Member 58 98-03-31
Director/Board Member 49 20-02-02
Director/Board Member 54 21-04-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 99,507,490 97,058,874 ( 97.54 %) 0 97.54 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
12.02 %
11,962,997 12.02 % 1 560 M $
Vanguard Fiduciary Trust Co.
9.758 %
9,710,328 9.758 % 1 266 M $
4,063,336 4.083 % 530 M $
Bellevue Asset Management AG
2.443 %
2,430,500 2.443 % 317 M $
Eaton Vance Management
2.332 %
2,320,653 2.332 % 303 M $
Renaissance Technologies LLC
1.998 %
1,988,546 1.998 % 259 M $
JPMorgan Investment Management, Inc.
1.738 %
1,728,970 1.738 % 225 M $
Geode Capital Management LLC
1.631 %
1,623,124 1.631 % 212 M $
Janus Henderson Investors US LLC
1.571 %
1,563,632 1.571 % 204 M $
BNY Mellon Investment Adviser, Inc.
1.523 %
1,515,022 1.523 % 198 M $

Holdings

NameEquities%Valuation
8,575,316 18.58% 71,346,629 $

Company contact information

Neurocrine Biosciences, Inc.

12780 El Camino Real

92130, San Diego

+858 617 7600

http://www.neurocrine.com
address Neurocrine Biosciences, Inc.(NBIX)